ElectroCore, a leader in non-invasive bioelectronic therapies, has completed the acquisition of NeuroMetrix and its Quell neuromodulation platform. The move is expected to enhance ElectroCore’s commercial reach, particularly within the VA Hospital System, while expanding its portfolio of treatments for chronic pain and wellness.
Key Highlights:
- Acquisition Terms: Each NeuroMetrix (NURO) share was exchanged for $4.49 per share and a contingent value right (CVR) tied to future sales milestones of Quell and DPNCheck, a diagnostic tool for peripheral neuropathy.
- Quell: This wearable, app-enabled platform helps manage fibromyalgia and lower-extremity chronic pain, contributing to ElectroCore’s expanding addressable market.
- Strategic Positioning: The acquisition positions ElectroCore to accelerate Quell’s adoption, particularly within veteran healthcare systems, while diversifying its offerings in non-pharmaceutical nerve stimulation.
With this acquisition, ElectroCore aims to leverage its established distribution channels to drive the growth of Quell and solidify its leadership in bioelectronic technology for chronic pain management.
Follow MEDWIRE.AI for the latest updates on innovations in pain management and bioelectronics.
